Stockwinners Market Radar for May 31, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EDT Cathie Wood's ARK Investment sold 23.3M shares of Nvidia today

20:11 EDT Cathie Wood's ARK Investment bought 233.1K Adaptive Biotechnologies shares today

19:25 EDT Four Corners Property Trust buys National Veterinary Assoc. property for $1.4M - Four Corners Property Trust is pleased to announce the acquisition of a National Veterinary Associates property for $1.4M. The property is located in Washington and is corporate-operated under a new long-term, triple net lease with annual rent bumps. The transaction was priced at a cap rate in range with previous FCPT transactions.

18:53 EDT Applied Materials CEO: We are innovating the way we innovate - In an interview on CNBC's Mad Money, Gary Dickerson said Silicon Valley is the innovation capital of the world. The CHIPS Act has been a catalyst, he noted. He expects the company to double its dividend over the next four years. Applied's backlog is "still pretty strong" and the company is performing well, he added. "We're right in the top of the first inning with AI," he said.

18:38 EDT Nvidia director sells $37.9M in common stock - In a regulatory filing, Nvidia disclosed that its director Tench Coxe sold 100K shares of common stock on May 26th in a total transaction size of $37.9M.

18:10 EDT Splash Beverage receives noncompliance notice from NYSE over 10-Q filing - Splash Beverage Group announced it had received a notice from the NYSE Regulation of noncompliance with the NYSE American continued listing standards as a result of the Company's delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2023. The Company was unable to file the 10-Q as reported on the Form 8-K filed with the SEC on May 30th, 2023. Earlier, on March 9, 2023, the Company had with the SEC filed the Form 8-K stating that the audit firm on record had changed structurally through a merger and was to be treated as a new firm. The Company and the premerger auditor had prepared the statements on time as in previous filings however the newly engaged auditor incorporated new procedures and an extra layer of partner approval requiring additional time to complete the review of the financial statements for the period ended March 31, 2023. The Company intends to file its 10-Q as soon as practicable. Robert Nistico, CEO, said, "We are working with the newly merged audit group as they transition and implement new processes and approvals that have unexpectedly delayed the final review and filing of our 10-Q and are working to file as soon as possible."

17:50 EDT Pfizer says FDA approves RSV prevention vaccine - Pfizer announced that the U.S. Food and Drug Administration has approved ABRYSVO, the company's bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. ABRYSVO is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains and was observed to be safe and effective. "A vaccine to help prevent RSV had been an elusive public health goal for more than half a century. Today's approval is a monumental step forward in delivering on Pfizer's commitment to help alleviate the significant burden of RSV in higher-risk populations, which includes older adults," said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer. "ABRYSVO will address a need to help protect older adults against the potentially serious consequences of RSV disease. We are extremely grateful to the clinical trial participants, study investigator teams and our dedicated Pfizer colleagues for their roles in making this vaccine available."

17:31 EDT Telesis Bio secures $28M in financing - Telesis Bio announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28M in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2M in gross proceeds. The financing is led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company's Chief Executive Officer and Founder, Todd R. Nelson, PhD. Under the terms of the Redeemable Convertible Preferred Stock and Warrant Purchase Agreement, immediately following the closing of the financing, Paul Meister, a partner at Novalis LifeSciences LLC, will be appointed to the company's board of directors, increasing the size of its board of directors from seven to eight. The company intends to use the proceeds from the financing for general corporate purposes. The financing is expected to close on June 2, 2023, subject to the satisfaction of customary closing conditions.

17:25 EDT Nvidia director sells $3.01M in common stock - In a regulatory filing, Nvidia disclosed that its director Persis Drell sold 7.8K shares of common stock on May 26th in a total transaction size of $3.01M.

17:17 EDT Lucid Group falls about 7% to $7.25 after announcing $3B offering

17:12 EDT CF Industries VP Barnard sells over $1M in company shares - CF Industries VP Douglas Barnard disclosed in a regulatory filing that he had sold 17,000 shares of company stock at $61.28 per share on May 30, for a total transaction amount of $1,041,743.

17:07 EDT Vision Sensing Acquisition says sponsor Vision Sensing extends deal to July 3 - Vision Sensing Acquisition a special purpose acquisition company, announced that its sponsor, Vision Sensing, has notified Continental Stock Transfer & Trust Company that it intends to extend the date by which the Company must consummate its initial business combination from June 3 to July 3 by depositing into the Company's trust account an aggregate of $72,562.86. In connection with the Extension, the Company intends to issue to its sponsor a non-interest bearing, unsecured promissory note in the principal amount of $72,562.86 as consideration for the funding. This will be the second of up to six one-month extensions that the Company is authorized to obtain under its amended and restated certificate of incorporation as recently amended on May 1.

17:01 EDT C3.ai falls 15% to $34.47 after Q4 results, FY24 guidance

16:51 EDT Cronos plans to exit existing U.S. hemp-derived CBD operations - Cronos Group announced its decision to streamline its operating structure by winding down and exiting its existing U.S. hemp-derived CBD-focused operations by the end of the second quarter of 2023. Cronos has made this decision to improve its cash flow in the near term and position itself to directly enter the U.S. THC market when the necessary changes in U.S. regulatory conditions occur. Consequently, beginning with the second quarter of 2023, the company intends to report its financial results under one consolidated segment and will no longer report the U.S. and Rest of World as separate segments. Cronos is also increasing its previously announced 2023 operating expense savings target from a range of $10M-$20M to a new range of $20M-$25M, partially due to its decision to wind down and exit its existing U.S. operations. In connection with the exit of its existing U.S. operations, Cronos expects to incur expenses in the second quarter of 2023, of up to $1.8M comprised of inventory write-offs, severance and other employee costs, and asset impairment charges. "We believe that one day, the U.S. will be one of the most important cannabis markets in the world," said Mike Gorenstein, Chairman, President and CEO, Cronos. "But we also believe our resources are best spent on staying laser-focused on becoming cash flow positive by driving cost savings and process efficiencies for our borderless adult-use products. We have the best balance sheet in the cannabis industry, with $836 million in cash and short-term investments and zero debt as of March 31, 2023. Achieving our goal to generate positive cash flow in 2024 will advance our industry-leading cash balance and put us in the best position to win in the U.S. once regulatory conditions change." The company is committed to maximizing the value of its global branded product portfolio. It anticipates bringing the Lord Jones brand back to its adult-use roots by launching it in the Canadian market in the fourth quarter of 2023.

16:46 EDT MSA Safety names Steve Blanco as Chief Operating Officer - Global safety equipment manufacturer MSA Safety announced that Steve Blanco has been elected President and Chief Operating Officer by the company's Board of Directors. Mr. Blanco who previously served as President of the company's Americas business segment, a position to which he was appointed in 2017. As President and COO, Mr. Blanco will oversee the continued implementation of the company's strategic initiatives across MSA's global portfolio. Nish Vartanian will continue to serve the company as Chairman and CEO.

16:40 EDT Solid Power appoints John Van Scoter as CEO - Solid Power announced that John Van Scoter has been appointed president, CEO, and a Class I Director of Solid Power, effective June 14. Van Scoter succeeds Dave Jansen, the interim CEO, president and chair of the company. Jansen will continue to serve as chairperson of the board and will support Van Scoter in an advisory role to ensure a seamless transition.

16:35 EDT Novan trading resumes

16:32 EDT Kinder Morgan boosts storage capacity on Texas intrastate system - Kinder Morgan announced its plan to expand the working gas storage capacity at its Markham Storage facility in Matagorda County along the Texas Gulf Coast. KMI has reached an agreement with Underground Services Markham, LLC, a subsidiary of Texas Brine Company LLC, to lease an additional cavern at Markham to provide more than 6 billion cubic feet of incremental working gas storage capacity and 650 million cubic feet per day of incremental withdrawal capacity on KMI's extensive Texas intrastate pipeline system. Anchor shippers have subscribed to approximately half of the available capacity under long-term agreements, and commercial in-service for the project is expected in January 2024. "During Winter Storm Uri, KMI's storage portfolio was critical to supplying human needs customers in Texas while also providing much needed supply to numerous electric generation facilities during the storm. We are pleased to increase our natural gas storage solutions to further support Texas customers, particularly during severe weather events," said KMI Natural Gas Midstream President Tom Dender. "Storage capabilities on highly utilized assets are critical to support Texas' ability to respond to an energy crisis and ensure energy reliability as renewables become a greater portion of the state's energy mix. This expansion will provide much needed capacity that could supply gas-fired electric generation facilities within ERCOT and provide electric service to well in excess of one million homes in Texas."

16:32 EDT Infobird regains compliance with Nasdaq minimum bid price requirement - Infobird received a notification letter from the Listing Qualifications Department of Nasdaq notifying the company that it has regained compliance with the Nasdaq Capital Market's minimum bid price requirement and that the matter is now closed.

16:25 EDT Veeva jumps 6% to $175.99 after Q1 results, FY24 guidance beat estimates

16:24 EDT Pure Storage jumps 7% to $30.89 after Q1 results beat estimates

16:23 EDT Nordstrom jumps 7% to $16.47 after Q1 results beat estimates

16:22 EDT DHT Holdings to acquire VLCC built in 2018 for $94.5M - DHT Holdings announced that it has entered into an agreement to acquire a VLCC built in 2018 at Hyundai Heavy Industries HHI for $94.5M.The vessel is scheduled to deliver during the third quarter of 2023. The Company will finance the acquisition with available liquidity and projected mortgage debt, and it is expected to be accretive to DHT's earnings per share. It was built to a high specification by its current owner, is fitted with an exhaust gas cleaning system and will further improve the DHT fleet efficiencies, amongst others its Annual Efficiency Ratio and Energy Efficiency Operational Index metrics. DHT's President & CEO, Svein Moxnes Harfjeld, comments: "We are constantly hunting high and low for opportunities that can bring value to our shareholders. As always, the devil is in the details and this is a sister of vessels built by us in 2018, a design with large deadweight and premium earning capabilities, fitting well into the trading patterns of our key customers. We expect this to become a good investment, delivering into a market with attractive prospects."

16:21 EDT Nordstrom reports Q1 gross profit margin up 110 bps y/y - The company's first quarter results reflected progress on its key priorities. Nordstrom Rack sales trends improved late in the quarter, with the strongest performance in April, primarily driven by increased penetration of strategic brands in its merchandise mix. Gross profit margin expanded by 110 basis points over last year, reflecting the company's focus on increasing inventory productivity. In addition, the company continued to deliver efficiencies through its supply chain initiatives, which contributed over 100 basis points of improvement in variable costs within selling, general and administrative expenses, helping to mitigate the impact of deleverage on lower sales.

16:19 EDT Cano Health issues stockholder presentation calling for board re-election - Cano Health has published an investor presentation to its investor relations website in connection with its upcoming Annual Stockholders' Meeting. Cano Health believes that it is meaningfully undervalued relative to peers based on its Medicare membership base, recent earnings performance of core operations, and cash burn per net new member. The company's plan consists of sharpening the company's focus on Medicare Advantage including conducting a process to divest non-core assets; unlocking embedded medical center profitability; streamlining operations; strengthening cash flows; and optimizing Cano Health's management team and governance. Over the past several months, the Board believes it has has implemented necessary and ongoing governance improvements, including the recent separation of the Chairman and CEO positions as well as a review and enhancement of certain company policies and procedures. The Board believes that the former directors resigned to launch a highly disruptive campaign intended to further their own short-term interests. The former directors have publicly stated their singular objective is to dismantle Cano Health's platform and sell it for parts. Cano Health urges stockholders to vote on the proxy card for re-election of the company's two independent directors and the proposed reverse stock split.

16:17 EDT M3-Brigade Acquisition III Corp. receives NYSE non-compliance notice - M3-Brigade Acquisition III Corp. announced that it has received a notice from the New York Stock Exchange indicating that the company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 with the SEC. The notice has no immediate effect on the listing of the company's stock on the NYSE

16:16 EDT FTC, DOJ fine Amazon $25M for children's privacy law violations - The Federal Trade Commission and the Department of Justice said they "will require Amazon to overhaul its deletion practices and implement stringent privacy safeguards to settle charges the company violated the Children's Online Privacy Protection Act Rule and deceived parents and users of the Alexa voice assistant service about its data deletion practices." According to a complaint filed by the Department of Justice on behalf of the FTC, Amazon prevented parents from exercising their deletion rights under the COPPA Rule, kept sensitive voice and geolocation data for years, and used it for its own purposes, while putting data at risk of harm from unnecessary access. In addition to the data deletion requirement in the proposed order, Amazon will be required to pay a $25M civil penalty. Other provisions of the proposed order include prohibiting Amazon from using geolocation, voice information, and children's voice information subject to consumers' deletion requests. Reference Link

16:15 EDT Novan reduced workforce by 50%, to explore sale of commercial assets - Novan announced that following an evaluation of its commercial and developmental stage assets, it has decided to sharpen its focus and resources on berdazimer gel, 10.3% and announced that it continues to explore strategic alternatives, with a focus on its commercial product portfolio and a sale or out-license of one or more of its commercial products. Novan conducted a review of its commercial and development portfolio of assets to determine a path to optimally deploy capital and maximize shareholder value. Following this review, the company, has initiated a process to explore a sale or out-license of its commercial assets, including RHOFADE, MINOLIRA, and CLODERM. The company will immediately reduce certain of its operating expenses currently supporting its commercial operations. The restructuring of the company's commercial business, impacting 39 employees, results in a reduction in force of approximately 50% of employees of the Company, primarily among its field sales representatives. The company estimates that it will incur approximately $0.9M in charges related to the reduction in force over a period of twelve months. The company took this step to concentrate its resources on pursuing the regulatory approval for the company's berdazimer gel, 10.3% product candidate.

16:12 EDT Okta reports Q1 RPO, or subscription backlog, up 9% from last year at $2.94B - Q1 cRPO, which is subscription backlog expected to be recognized over the next 12 months, was $1.70B, up 20% compared to the first quarter of fiscal 2023.

16:11 EDT Barnes & Noble Education sees FY23 adjusted EBITDA ($10M)-($5M) - The company expects to report consolidated full year non-GAAP Adjusted EBITDA from continuing operations in the range of $(10) million to $(5) million, compared to $(10.3) million in the prior year period. The Company's fiscal 2023 non-GAAP Adjusted EBITDA from continuing operations is below its guidance due to lower than expected fourth quarter revenue and lower fourth quarter gross profits, which included a shift in the mix of buying patterns from physical textbooks to lower-margin digital course materials within the Company's a la carte course material model. "While fiscal 2023 did not meet our financial expectations, we believe the strategic actions taken throughout the year position BNED on the path to profitable growth," said Huseby. "During the second half of fiscal 2023, we made substantial progress on our cost reduction initiatives to better align our overall expenses and resources with the secular trends of declining enrollment and the proliferation of digital course materials. We also made meaningful progress with our institutional partners to accelerate their transition to our FDC equitable access model. We expect to launch a significant number of new schools on the FDC model in the Fall of 2023 and remain confident about FDC's contribution to BNED's long-term profitable growth."

16:10 EDT Salesforce reports Q1 current RPO $24.1B, up 12% from last year

16:04 EDT Acorda Therapeutics to conduct 1-for-20 reverse stock split - Acorda Therapeutics announced that it will conduct a reverse stock split of its outstanding and authorized shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 4:01 p.m. Eastern Time, on June 2, 2023. The Company's common stock will begin trading on a post-split basis at the market open on June 5, 2023. The reverse stock split is being effected to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on The Nasdaq Global Select Market.

16:00 EDT Novan trading halted, news pending

15:07 EDT Nexters Inc trading resumes

14:57 EDT Nexters Inc trading halted, volatility trading pause

14:43 EDT Grizzly Research says Bluebird Bio 'has entered death spiral' - In a recently published report, Grizzly Research says "Bluebird Bio, once a darling of the pre-revenue hot-biotech-money crowd, has entered its death spiral. Access to capital for bringing any product to market becomes increasingly dilutive and forces management into additional stock sales. Its core technology has been eclipsed by newer, safer, and more reliable treatment pathways. CEO Andrew Obenshain is now compelled to parrot a less and less credible portrayal of patient populations, treatment risks, and insurance reimbursement uptakes for his drug candidates. In this researcher's view, Bluebird's time for achieving escape velocity is past, and the forces of gravity pulling it toward a liquidation or dissolution scenario can no longer be escaped." "Considering Bluebird's operational cash needs and dire prospects for commercial success, we believe the company will have to continue to dilute shareholders for the foreseeable future," the report further states. Reference Link

14:20 EDT Bulldog says Tortoise Energy should explore strategic options - Bulldog Investors disclosed a 5.06% stake in Tortoise Energy Independence Fund, which represents 88,776 shares. The filing allows for activism. Bulldog believes "management should consider strategic options to maximize shareholder value."

14:13 EDT Tencent's Riot Games delays League of Legends season amid LCS player walkout - Naz Aletaha, Riot Games' global head of League of Legends esports blogged in part earlier: "There's been a lot of discussion over the past few days about the North American Challenger League,NACL, and the LCS player walkout...There's been a lot of talk about the current state of esports, including esports' long-term future. Over the last few months we've been more focused than ever on meeting the teams' needs for economic sustainability. ...All that said, a top priority for us always is the fans. While last week we immediately put in place contingency plans to begin the LCS season on Thursday, we ultimately decided that it would not hold true to our values that Riot's esports offers our players and fans a showcase for the best competitive League of Legends. Nothing but putting the best players in North America on the stage at Riot Games Arena is acceptable. So we informed LCSPA leadership today that we will delay the LCS season for the next two weeks. Hopefully, this two-week window will give us time for productive dialogue between the LCSPA, teams, and the league and then resume LCS competition this summer. The LCS will not be penalizing the teams for not fielding their rosters during this two-week period to allow everyone space to focus on constructive dialogue. We are doing our best to ensure LCS employees, contractors, and others supporting the LCS are not negatively impacted by the delay..." Reference Link

14:00 EDT Maravai LifeSciences trading halted, volatility trading pause

13:20 EDT North American rail traffic down 4.1% for the week ending May 27 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending May 27. For this week, total U.S. weekly rail traffic was 480,998 carloads and intermodal units, down 4.8% compared with the same week last year. Total carloads for the week ending May 27 were 235,307 carloads, up 3.5% compared with the same week in 2022, while U.S. weekly intermodal volume was 245,691 containers and trailers, down 11.6% compared to 2022. North American rail volume for the week ending May 27, on 12 reporting U.S., Canadian and Mexican railroads totaled 337,575 carloads, up 1.7% compared with the same week last year, and 331,924 intermodal units, down 9.3% compared with last year. Total combined weekly rail traffic in North America was 669,499 carloads and intermodal units, down 4.1%. North American rail volume for the first 21 weeks of 2023 was 13,563,680 carloads and intermodal units, down 4.1% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Greenbrier (GBX), Trinity Industries (TRN), FreightCar America(RAIL) and Wabtec (WAB). Reference Link

13:13 EDT onsemi, Vitesco Technologies sign SiC long-term suply agreement - Vitesco Technologies (VTSCY) and onsemi (ON) announced a 10-year long-term supply agreement worth $1.9B for silicon carbide products to enable Vitesco Technologies' ramp in electrification technologies. Vitesco Technologies is providing an investment of $250M to onsemi for new equipment for SiC boule growth, wafer production and epitaxy to secure access to SiC capacity. The equipment will be used to produce SiC wafers to support Vitesco Technologies' growing SiC demand. In parallel, onsemi will continue to invest substantially into end-to-end SiC supply chain. addition, Vitesco Technologies and onsemi will collaborate on optimized customer solutions for Vitesco Technologies.

13:06 EDT Apple says App Store facilitated billings, sales grew 29% year-over-year in 2022 - Apple announced that an independent study by economists from Analysis Group found the App Store ecosystem facilitated $1.1 trillion in developer billings and sales in 2022. "The App Store continues to create incredible opportunity for developers around the world, with more than 90% of the billings and sales accruing solely to developers and businesses of all sizes - without any commission paid to Apple. Additionally, new analysis from the Progressive Policy Institute found the iOS app economy now supports more than 4.8 million jobs across the U.S. and Europe, with approximately 2.4 million in each region... The economists from Analysis Group estimate that last year, App Store developers generated $910 billion in total billings and sales from the sale of physical goods and services, $109 billion from in-app advertising, and $104 billion for digital goods and services... Developer billings and sales increased by 27 percent between 2019 and 2020; 27 percent between 2020 and 2021; and 29 percent between 2021 and 2022. Small developers in particular found tremendous success on the App Store - outpacing larger developers by growing their revenue by 71 percent between 2020 and 2022. The economists at Analysis Group believe growth rates of this kind are positive indicators, consistent with a flourishing marketplace full of dynamism, innovation, and competition," Apple stated. Tim Cook, Apple's CEO, added: "As this report shows, the App Store is a vibrant, innovative marketplace where opportunity thrives, and we're as committed as ever to investing in developers' success and the app economy's future." Reference Link

12:32 EDT Farallon comments on election of all three nominees to Exelixis' board - Farallon Capital Management, which manages funds that own approximately 7.8% of the outstanding shares of Exelixis, making it the company's largest active shareholder, commented on the preliminary results of Exelixis' 2023 Annual Meeting of Shareholders, including the election to the Board of Directors of all three Farallon director candidates: Tom Heyman, Dave Johnson and Bob Oliver. Farallon stated: "We are pleased that our three exceptional nominees were elected to the Board of Exelixis and would like to thank our fellow shareholders for their engagement and overwhelming support at the Annual Meeting. Tom, Dave and Bob are ready to work constructively with the rest of the Board to fulfill the mandate they received from shareholders and help the Company better allocate capital and focus its R&D efforts. We expect the remaining incumbent directors to heed the clear message of this election and recognize that Exelixis must embrace change to achieve its full potential for patients and shareholders. We look forward to seeing what this newly comprised Board can help achieve at Exelixis."

12:17 EDT Thunder Bridge files proxy statement in connection with special meeting - Thunder Bridge Capital Partners, a SPAC publicly listed on the Nasdaq Global Market, announced that it is working closely with Coincheck Group B.V., a consolidated subsidiary of Monex Group, Inc., which will be a holding company of Coincheck, to complete the previously announced merger which will result in CCG becoming a publicly listed company on Nasdaq pursuant to the Business Combination Agreement, dated March 22, 2022, among THCP and CCG and certain of its affiliates. In response to the U.S. SEC's prolonged registration review process, THCP filed a proxy statement on May 31, 2023 in connection with a special meeting of stockholders of THCP that will be held on June 21, 2023, which includes, among other things, a proposal to amend its amended and restated certificate of incorporation to extend the date by which THCP must consummate a de-SPAC transaction from July 2, 2023 to July 2, 2024. In light of the above, the parties have agreed to amend the Business Combination Agreement to extend the deadline for completing the CCG De-SPAC Transaction for one year, subject to stockholder approval of the Extension Proposal at the THCP Stockholders Meeting.

12:00 EDT Capri Holdings falls -11.9% - Capri Holdings is down -11.9%, or -$4.71 to $34.87.

12:00 EDT Advance Auto Parts falls -33.8% - Advance Auto Parts is down -33.8%, or -$37.95 to $74.25.

12:00 EDT Twilio rises 9.4% - Twilio is up 9.4%, or $5.91 to $68.58.

11:56 EDT Six Flags offers free lifeguard training for up to 4,500 lifeguards - The company said, "Six Flags Entertainment Corporation is looking for dedicated team members that want to save lives. Six Flags is so passionate about safety that the company is offering to train up to 4,500 lifeguards for free. The robust lifeguard training includes much more than water skills. All Six Flags lifeguards are trained and credentialed using the world-renowned Ellis & Associates International Lifeguard Training Program. Training includes healthcare provider CPR, emergency oxygen support, automated external defibrillator, standard first aid, incident prevention and water rescue techniques."

11:31 EDT Toyota to assemble three-row BEV at Toyota Kentucky starting in 2025 - Advancing its commitment to vehicle electrification and building where it sells, Toyota announced that it will assemble an all-new, three-row, battery electric SUV at Toyota Kentucky starting in 2025. The company's first U.S.-assembled BEV will be powered by batteries from Toyota North Carolina, it said. The new battery plant, which is currently under construction, will receive an additional $2.1B investment to support the company's drive toward carbon neutrality, Toyota stated. We are committed to reducing carbon emissions as much as possible and as soon as possible," said Ted Ogawa, president and CEO officer, Toyota Motor North America.

11:05 EDT Flushing Financial announces 1M increase in share repurchase authorization - Flushing Financial Corporation announced that the Board of Directors has authorized an increase in the purchase of its common stock by 1,000,000 shares. Stock can be purchased from time to time, in the open market or through private transactions, subject to market conditions. There is no expiration or maximum dollar amount under this authorization. From April 1, 2023, through May 25, 2023, the Company repurchased 270,338 shares at an average price of $11.47 and has 164,608 shares remaining under its previous authorization. The combined remaining authorization is 1.2 million shares. John R. Buran, the company's President and CEO stated: "The Board of Directors authorized an increase of 1 million shares to our current repurchase program. We remain confident in our strong liquidity and conservatively positioned business model. Over 88% of our loan portfolio is real estate collateralized with average loan to values of less than 37%, and strong debt service coverage ratio of 1.9 times. The increase in the share repurchase authorization, and our recent quarterly dividend announcement, highlights our commitment to shareholders."

10:25 EDT SunCar Technology Group Inc trading resumes

10:20 EDT SunCar Technology Group Inc trading halted, volatility trading pause

10:03 EDT US Aviation Academy joins Spirit Wings Pilot Pathway program - Spirit Airlines announced that US Aviation Academy in Denton, Texas, is the latest partner to join the Spirit Wings Pilot Pathway program. The flight school offers comprehensive pilot training and is conveniently located near one of Spirit's Pilot crew bases at Dallas Fort Worth International Airport, which provides graduates with opportunities to build relationships and progress to a career as a Spirit First Officer.

10:00 EDT C3.ai falls -9.5% - C3.ai is down -9.5%, or -$4.17 to $39.78.

10:00 EDT Centerra Gold rises 13.7% - Centerra Gold is up 13.7%, or 75c to $6.22.

10:00 EDT Alerian Midstream Energy Index rises 1245.0% - Alerian Midstream Energy Index is up 1245.0%, or $436.07 to $471.09.

09:48 EDT A2Z Smart Technologies receives smart cart order from Morton Williams - A2Z Smart Technologies is proud to announce that it has entered into an agreement with Morton Williams, an established retailer in the New York metropolitan area, for the order of 100 specially designed 75-liter smart carts, tailored for deployment in urban supermarkets. The order is to encompass an upfront payment and monthly subscription payments. This collaboration showcases the potential of A2Z's smart cart platform solution, empowering retailers like Morton Williams to optimize their operations, enhance customer experiences, and generate additional revenue.

09:47 EDT OneMain ordered by CFPB to pay $20M for deceptive sales practices - The Consumer Financial Protection Bureau has ordered installment lender OneMain Financial to pay $20M in redress and penalties for failing to refund interest charged to 25,000 customers who cancelled purchases within a purported "full refund period," and for deceiving borrowers about needing to purchase add-on products to receive a loan. OneMain will pay $10M in refunds to consumers it harmed, and an additional $10M penalty to the CFPB's victims relief fund. "OneMain pressured its employees to load up its loans with extra charges through false promises of easy cancellation with full refunds," said CFPB Director Rohit Chopra. "We are ordering OneMain to refund borrowers it cheated and to clean up its business practices."

09:47 EDT HP Enterprise falls -10.1% - HP Enterprise is down -10.1%, or -$1.57 to $13.95.

09:47 EDT Centerra Gold rises 9.0% - Centerra Gold is up 9.0%, or 49c to $5.96.

09:47 EDT Alerian Midstream Energy Index rises 1247.6% - Alerian Midstream Energy Index is up 1247.6%, or $436.98 to $472.00.

09:41 EDT Knightscope receives two new contracts for K5 Autonomous Security Robots - Knightscope announced that it has two new contracts to deploy K5 Autonomous Security Robots. A Washington casino and a Texas multi-tenant, Class-A workspace provider are the latest to subscribe to the company's Machine-as-a-Service security solution.

09:35 EDT Reinsurance Group, Legal & General partner for $309M PRT transaction - Legal & General Retirement America (LGGNY) and Reinsurance Group of America, Incorporated (RGA) entered into a $309 million pension risk transfer transaction with PPG (PPG). The lift-out covers over 4,000 retirees and beneficiaries with benefits under a defined benefit pension plan sponsored by PPG. LGRA is lead administrator and will be fully responsible for the service and administration of all participants transferred as part of the lift-out.

09:32 EDT Nevada reports April statewide gaming win up 2.77% to $1.16B - Nevada reports April Las Vegas Strip gaming win up 5.27% versus last year to $624.72M. Publicly traded companies in the gambling space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:30 EDT ACI Worldwide advances 3% after CEO appointment, reiteration of guidance - "While we have more work to do to fully capitalize on the opportunities ahead, we have a strong roadmap and are continuing to execute. We remain on track to achieve our previously stated guidance for revenue growth and adjusted EBITDA, and we will continue to maintain a disciplined approach to capital allocation and portfolio management. I believe we are well-positioned to build on our current momentum as we continue to enable leading corporations, fintechs, financial disruptors and merchants to drive the real-time digital transformation of payments and commerce," said management.

09:26 EDT LPL Financial: Individual Financial joins broker-dealer, RIA, custodial platform - LPL Financial LLC announced today that financial advisor Neil Pettes, CFP and the team at Individual Financial Services have returned to LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $400 million in advisory, brokerage and retirement plan assets, and joins LPL from Cambridge Investment Research, Inc. Located north of Pittsburgh in Wexford, Pa., Individual Financial Services launched in 1971 by Founding Partner Martin Mancuso with a focus on providing superior client service, approaching each relationship with integrity, trust and commitment. He understood that each client has unique financial needs, which has been a guiding principle for the firm over the past four decades.

09:20 EDT Verastem announces 1-for-12 reverse stock split - Verastem announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock. Verastem's stockholders approved an amendment to Verastem's Restated Certificate of Incorporation to effect the reverse stock split at Verastem's annual meeting of stockholders held on May 15. The reverse stock split is intended to increase the per share trading price of the Verastem's common stock to ensure Verastem will satisfy the price requirement for continued listing on the Nasdaq Global Market, and potentially attract a broader range of investors. Pursuant to the Amended Charter, the reverse stock split will become effective at 5:00 p.m. Eastern Time on May 31 and the company expects that its common stock will open for trading on June 1 on the Nasdaq Capital Market on a split-adjusted basis under the company's existing trading symbol "VSTM".

09:18 EDT Westhaven Gold announces drill results at Shovelnose Gold Property - Westhaven Gold announced results from its drill campaign at its 100% owned 17,623-hectare Shovelnose gold property. Shovelnose is located within the prospective Spences Bridge Gold Belt, which borders the Coquihalla Highway 30 kilometres south of Merritt, British Columbia. Gareth Thomas, Westhaven's President & CEO, stated, "Drill step-outs continue to intersect high-grade gold near surface at the Franz Zone. Drilling is planned to the northwest of these intercepts as we continue to chase this mineralization along strike. A drill is currently turning at the new and undrilled Kirton target, which is located 2 kilometres from the Zone One Trend. Westhaven's fully financed 2023 exploration program includes testing targets off the main Zone One Trend, including the Kirton, Romeo and Hydrothermal Breccia No.2 targets." Westhaven is reporting assays for 4 holes from its drill campaign at Shovelnose. An additional 6 holes are in the lab pending assays. Recent Highlights: SN23-337 : Franz: 24.95 metres of 14.66 g/t gold and 35.52 g/t silver, including 13.0m of 27.25 g/t Au and 52.44 g/t Ag, including 0.66m of 280 g/t Au and 222 g/t Ag. 15.9m of 1.49 g/t Au and 27.69 g/t Ag,including 2.0m of 6.55 g/t Au and 101.3 g/t Ag. SN22-335 : Franz: 14.33m of 1.59 g/t Au and 2.7 g/t Ag, including 1m of 16.3 g/t Au and 4.8 g/t Ag. 3.35m of 3.08 g/t Au and 3.27 g/t Ag, including 1.16m of 7.2 g/t Au and 4.29 g/t Ag. SN23-336 : Franz: 16.99m of 1.01 g/t Au and 15.94 g/t Ag, including 3.0m of 2.76 g/t Au and 40.76 g/t Ag. 4.0m of 1.71 g/t Au and 35.49 g/t Ag, including 0.74m of 6.29 g/t Au and 107 g/t Ag.

09:15 EDT Femsa to divest minority investment in Jetro Restaurant Depot - Fomento Economico Mexicano announced that consistent with its FEMSA Forward strategy as communicated on February 15, 2023, it has entered into a definitive agreement to divest its minority investment in Jetro Restaurant Depot and related entities Subject to customary closing conditions, FEMSA will receive total cash consideration of $1,400 million, with approximately $467 million payable on closing in the second quarter of 2023, and the remainder payable over two years.

09:12 EDT HUMBL extends limitations for Series B Preferred Stock Conversions - HUMBL announced that its Board of Directors and Series B stockholders have approved an amendment to HUMBL's certificate of incorporation to extend the limitations on the conversions of its Series B preferred stock. These limitations include preventing the Series B holders from converting any Series B preferred stock from June 2023 through September 2023 and limiting their conversions to 500 Series B shares per month from October 2023 to June 2024. From July 2024 to December 2024, conversions will be limited to 1,000 Series B shares per month. The amendment to the certificate of incorporation will take effect on June 1, 2023. The Series B preferred shares are not registered under Section 12 of the Exchange Act. This is one of several measures that HUMBL is taking as part of its broader restructuring plan to recapitalize the company, consolidate and retire existing debt and reduce dilution. This restructuring is designed to drive shareholder value and strengthen the balance sheet of the company.

09:09 EDT Rocket Pharmaceuticals up 6% after receiving EMA PRIME designation for RP-A501 - Shares of Rocket Pharmaceuticals are up $1.23 per share or 5.96% ahead of the open on Wednesday after announcing the EMA has granted Priority Medicines PRIME designation to RP-A501, the Company's investigational adeno-associated virus AAV-based gene therapy for the treatment of Danon Disease.

09:07 EDT CareCloud's medSR division to showcase healthcare IT consulting services - CareCloud announced that its medSR division will be attending and exhibiting in booth 410 at the highly anticipated 2023 MUSE Inspire Conference. The conference will be held from June 7-10, 2023, at the Gaylord Rockies Resort & Convention Center in Aurora, Colorado. By offering a holistic approach to healthcare technology solutions, medSR ensures that organizations receive the support they need at every stage of implementation and operation. medSR's proficiency extends across more than 100 implementations and optimizations on various MEDITECH platforms, including Expanse, Ambulatory, 6.1, 6.0, Client/Server, and MAGIC. Their comprehensive services include project management, MEDITECH READY-certified consultants, IT staffing, interim leadership, training, and activation. Their management team and professional consultants offer extensive MEDITECH and operational experience, ensuring that client objectives are met and exceeded cost-effectively.

09:06 EDT Remark Holdings wins first phase of rollout by Rio de Janeiro police department - Remark Holdings announced it has won the first phase of a rollout by the Rio De Janeiro police department to equip their existing police car fleet with license plate and facial recognition capabilities. The deployment, scheduled to be completed over the next 120 days, is a 30-month recurring revenue subscription contract valued at over $6M. The current technical due diligence period, when passed, will immediately grant additional revenue opportunities for Phase 2 and Phase 3. Remark AI partnered with iProp.Tech, a local Brazilian system integrator to execute and implement the requirements requested by the Rio De Janeiro police department.

09:05 EDT 180 Degree Capital discloses votes on proposals from Comscore - 180 Degree Capital (TURN) has voted its approximately 6% of outstanding common stock as follows on the proposals included in the proxy statement for the 2023 Annual Meeting of Stockholders for Comscore, Inc. (SCOR): to elect Nana Banerjee, David Kline, Kathi Love and Brian Wendling as Class I directors to serve for terms expiring at SCOR's 2026 annual meeting of stockholders, to hold office until their respective successors have been duly elected and qualified; 180 WITHHELD votes for all nominated directors to emphasize its position that SCOR's Board has not taken action for the benefit of all stakeholders of SCOR. to approve, on a non-binding advisory basis, the compensation paid to SCOR's named executive officers; 180 voted FOR this proposal. to ratify the appointment of Deloitte & Touche LLP as SCOR's independent registered public accounting firm for the fiscal year ending December 31, 2023; 180 voted FOR this proposal. to approve an amendment to SCOR's Amended and Restated 2018 Equity and Incentive Compensation Plan to increase the number of shares of SCOR's common stock, par value $0.001 per share available for grant by 10,000,000; 180 voted FOR this proposal. to adopt an amendment to the Certificate of Designations of SCOR's Series B Convertible Preferred Stock, par value $0.001 per share to permit us to pay annual dividends on the Series B Preferred Stock in the form of cash, shares of Common Stock, additional shares of Series B Preferred Stock, or a combination thereof, in each case in accordance with the amendment and as elected by members of SCOR's Board of Directors who have not been designated by, and are not affiliated with, any holder of Series B Preferred Stock, and make certain other clarifying and conforming changes to the Certificate of Designations, including with respect to intended tax treatment; 180 voted AGAINST this proposal primarily due to our opposition to the ability this proposal would provide to pay annual dividends in Series B Preferred Stock. to adopt an amendment to SCOR's Amended and Restated Certificate of Incorporation to authorize additional shares of preferred stock, par value $0.001 per share in order to permit us to issue additional shares of Series B Preferred Stock and other preferred stock and pay annual dividends in the form of Series B Preferred Stock, in accordance with the Certificate of Designations amendment and if elected by the Disinterested Directors; and 180 voted AGAINST this proposal primarily due to our opposition to the ability this proposal would provide to pay annual dividends in Series B Preferred Stock. to approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of Common Stock or Series B Preferred Stock as annual dividends on the Series B Preferred Stock, in accordance with the terms of the Certificate of Designations amendment and if elected by the Disinterested Directors. 180 voted AGAINST this proposal primarily due to our opposition to the ability this proposal would provide to pay annual dividends in Series B Preferred Stock.

09:04 EDT NeuroMetrix announces clinical trial results of Quell - NeuroMetrix noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial of Quell titled "Wireless transcutaneous electric nerve stimulation for chemotherapy-induced peripheral neuropathy: A proof-of-concept, placebo-controlled, randomized clinical trial." The abstract will be published at the 2023 American Society of Clinical Oncology annual meeting to take place June 2-6 in Chicago, IL. The principal investigator is Dr. Jennifer Gewandter of the University of Rochester School of Medicine and Dentistry. The trial leveraged the National Cancer Institute Community Oncology Research Program. The study was a phase II, multi-site, double blinded, randomized, sham-controlled trial. The study authors concluded "A RCT of an app-controlled, wireless TENS device for chronic CIPN with excellent adherence and retention rates is feasible in NCORP. Preliminary efficacy evidence suggests that TENS is promising for pain and cramping from CIPN ... A confirmatory RCT of TENS for painful CIPN is highly warranted." The abstract is available at link and the study details are available at NCT04367480. "These efficacy results from a sham-controlled RCT of Quell in CIPN are exciting and consistent with an earlier published open-label study. CIPN is very difficult to manage, with no FDA approved treatments. As evidenced by its designation from the FDA as a breakthrough device for chronic CIPN, Quell offers the potential for a safe and effective treatment that can be administered at home," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "We look forward to obtaining further details on the trial results over the coming months and will correspondingly finalize our regulatory strategy, potentially to include a near term regulatory submission for a Quell CIPN indication. We are also enthusiastic about continuing to support Dr. Gewandter and her colleagues at NCORP as they pursue a confirmatory trial that further investigates the clinical benefits of Quell in CIPN."

09:02 EDT Cardinal Health launches payment solutions powered by Square - Cardinal Health launched modern payment solutions, powered by Square, to help independent pharmacies increase operational efficiency, stay current with customer payment preferences, and access integrated software tools for their business. An in-store payment solution, Modern Payments Processing, that runs on Square Terminal hardware and enables pharmacies to offer patient payment flexibility in the store or in the field, privacy, and compliance. Additional pharmacy management systems can also seamlessly integrate with Square's Terminal API to offer pharmacies an end-to-end payment solution.

09:02 EDT Ecarx announces mass production of intelligent cockpit for Changan Mazda - ECARX announced the mass production of intelligent cockpit product customized for Changan Mazda on its CX-50 model, based on ECARX's E02 intelligent cockpit computing platform. Over 770,000 units of ECARX E02 intelligent cockpit computing platform have been produced and equipped on 26 vehicle models from various OEM brands. ECARX E02 intelligent cockpit computing platform has obtained comprehensive certifications of quality safety management system, including the AEC-Q104 auto-grade qualification, meeting clients' high quality demand, consolidating highly efficient SoC, 4G communication module and power management chips inside, and helping clients significantly reduce required components, simplify supply chain, as well as lower development difficulty and manufacturing costs, as compared with single chip product.

08:59 EDT SM Energy appoints Julio Quintana as Chairman of the Board of Directors - SM Energy announced that, consistent with the succession plans previously disclosed in the Company's proxy statement, the Board of Directors of the Company has appointed Julio Quintana as Chairman of the Board of Directors. Quintana has been a director of the Company since 2006. Quintana replaces William Sullivan as Chairman, who has served as a Director since 2004 and Chairman since 2009. Sullivan will continue as a Director of the Company. As a result of this change, the Company updates participation on certain Board Committees as follows: Mr. Quintana will resign from the Board Committees on which he currently serves; Mr. Sullivan will join the Environmental, Social and Governance Committee and the Compensation Committee; and Carla Bailo will assume the role of Chairperson of the Environmental, Social and Governance Committee.

08:54 EDT QualTek Services receives delisting notification from Nasdaq - QualTek Services announced that it was notified by the Listing Qualifications Department of Nasdaq that Nasdaq had determined to delist the company's common stock as a result of the company's commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code. Nasdaq informed the company that trading in the company's common stock would be suspended at the opening of business on June 2.

08:44 EDT ReElement signs lithium offtake, partnership agreements with ALE - American Resources subsidiary, ReElement Technologies signed a partnership with American Lithium Energy Corporation to enhance the current supply chain for lithium-ion batteries to the energy storage industry by supplying battery-grade materials, investing in and co-locating advanced refining capacity with ALE's battery manufacturing. Through this agreement, ReElement Technologies will supply the high-purity lithium and other refined battery minerals to be used in creating ALE's state-of-the-art batteries that are used in a variety of applications and industries including medical, aerospace, defense, and electric vehicles. The partnership between ReElement Technologies and ALE initially targets the following key agreements: An offtake agreement between ReElement Technologies and ALE whereby ReElement Technologies will supply ALE high-purity, battery-grade lithium and other key minerals that will be used by ALE's suppliers to provide ALE domestically sourced material for their battery manufacturing process. A supply agreement where ALE will provide ReElement Technologies feedstocks such as end-of-life batteries, non-spec cells and manufacturing scrap to be used by ReElement Technologies in their patented chromatography process for refining back into ultra-high pure, battery-grade minerals at both ReElement Technologies' currently operating and planned facilities, and other locations identified between the parties. Co-locating each company's respective operations directly alongside the others creating a seamless and sustainable production line where ReElement Technologies will place its refining operations alongside ALE's, providing a method of recycling waste and end-of-life materials directly back into ALE's battery manufacturing process. Due to the highly favorable environmental and permitting aspects of ReElement Technologies' modular refining capacity, the Company can efficiently locate its production lines alongside almost any facility with minimal incremental cost to its partner. Concurrent with the partnerships, American Resources and affiliates will invest up to $3,000,000 into ALE as a lead investor in a capital raise conducted by ALE to help accelerate the company's production expansion and product innovation.

08:41 EDT Wag! Group set to join Russell Microcap Index June 26 - Wag! is set to join the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes. "We're honored to have been identified by Russell to join their ecosystem of Indexes and to be included in the index in 2023," said Wag! CFO, Alec Davidian. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.1T in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

08:40 EDT Trust Stamp announces notice of allowance for new U.S. patent - Trust Stamp announced that it has received a Notice of Allowance for an additional patent by the United States Patent and Trademark Office. This Notice of Allowance follows an previous patent allowance announced earlier this month. The patent titled, "Systems and Methods for Identity Verification via Third-Party Account," uses a proprietary process to establish control of one or more third-party accounts as a primary or secondary identity authentication factor and is intended to complement Trust Stamp's AI-generated Irreversibly Transformed Identity Token technology. Andrew Gowasack, Trust Stamp's President, commented, "With fraudulent transactions increasing at an alarming rate, multi-factor authentication is critical for all types of digital transactions. Trust Stamp provides not only a biometric-based privacy-first solution with the IT2 and Biometric Multi-Factor Authentication process, but also a suite of non-biometric tools to complement the IT2. This patent addresses our ability to utilize evidence of the user's control of third-party accounts, including social-media accounts, for identity authentication."

08:39 EDT 8x8 appoints Samuel Wilson as CEO and board member effective May 26 - 8x8 announced the appointment of Samuel Wilson as the company's Chief Executive Officer and a member of the Company's Board of Directors, effective May 26. Wilson has served as interim CEO since November 2022, while the Board conducted an extensive search.8x8 Appoints Samuel Wilson as CEO. "Sam's performance during his tenure as interim CEO has been outstanding and made him the clear choice for CEO," said Jaswinder Pal Singh, Chairman of the Board at 8x8. "He has demonstrated remarkable leadership skills, a deep understanding of the industry, and a clear vision for the future of 8x8. He has a deep commitment to delivering shareholder value and we have full confidence that he is the right person to lead the company into its next phase of growth and success."

08:38 EDT Else Nutrition expands distribution to over 900 locations in Canada - ELSE NUTRITION HOLDINGS expanded its distribution in the Canadian market with Canada's largest pharmacy, on the shelf at over 900 locations across 11 provinces and territories. The national rollout in late May 2023 will focus on Else Toddler Formula, the highest-ranked seller within Else Nutrition's portfolio. This marks a major milestone for Else Nutrition, which launched formally in Canada in August 2022. Canadian consumers will now be able to find Else's plant-based Toddler Formula, now widely distributed in another one of Canada's core retailers, this time within the Canadian National Drug Channel.

08:37 EDT Honeywell: Q2 on track, 'confident' in FY outlook - Comments taken from the Morgan Stanley Captains of Industry Summit.

08:36 EDT BP selects Honeywell's Ecofining technology to support production of SAF - Honeywell (HON) announced that bp (BP) selected Honeywell's Ecofining technology to help support the production of sustainable aviation fuel at five bp facilities across the globe. Honeywell UOP Ecofining technology will be installed at the following bp sites: Cherry Point refinery in Blaine, Washington; Rotterdam II refinery in Rotterdam, Netherlands; Lingen refinery in Lower Saxony, Germany; Castellon de la Plana refinery in Castellon, Spain and Kwinana Oil refinery in Kwinana, Australia.

08:34 EDT Lightwave Logic awarded patent for nonlinear optical chromophores - Lightwave Logic announced the issuance of a U.S. patent for an advanced chemical structural design that enhances the overall performance of non-linear organic optical chromophores using a novel thiophene bridge. The patent - entitled "Nonlinear Optical Chromophores, Nonlinear Optical Materials Containing the Same, and Uses Thereof in Optical Devices" details an innovative organic chromophore design using a novel 'thiophene bridge' to significantly improve material performance in a production environment. This is accomplished by designing thiophene-containing bridging groups that are positioned between the electron-donating and electron-accepting ends of the chromophore. These designs provide nonlinear optical chromophores with significantly improved optical properties and improved stability.

08:34 EDT Microbot Medical announces LIBERTY Robotic Surgical System achieves milestone - Microbot Medical announces that an additional milestone was achieved when medical professionals experienced the Company's LIBERTY Robotic Surgical System as part of a formative study. The study was designed to enable medical professionals, including physicians and Cath-lab technicians, to use and experience LIBERTY in a real-use simulated environment. The study was performed and managed by experts from a company specializing in conducting Human Factors and Usability Engineering tests of medical devices. The study included five teams, each consisting of an interventional radiologist and a Cath-Lab technician and simulated the expected clinical setup and use of the LIBERTY Robotic Surgical System. All participants were successfully trained on the system prior to their participation and the study validated that the LIBERTY Robotic Surgical System operation and setup are intuitive. "Educating and establishing close relationships with our target audience enables the Company to gain valuable feedback and increase awareness to our unique system. In parallel to our regulatory and pre-clinical efforts, we invest in receiving endorsements from leading experts and institutes which we believe will allow us to leverage our path to the clinical stages and later on to the market," commented Eyal Morag, Chief Medical Officer.

08:32 EDT Compass Pathways' co-founder Malievskaia to step down as CIO - COMPASS Pathway announced that Co-founder and Chief Innovation Officer, CIO, Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the COMPASS Pathways Board of Directors, while her executive responsibilities will be carried forward by the existing executive team. Together with George Goldsmith and Lars Wilde, Katya co-founded COMPASS Pathways in 2017, determined to bring much needed innovation to the field of mental health care.

08:29 EDT Avis Budget jumps 4% to $170 in pre-market after Deutsche Bank upgrade

08:27 EDT Wells Fargo has seen outsize card spend relative to outlays, says CEO

08:26 EDT Wells Fargo CEO: 'Good decision' to focus on credit card business

08:24 EDT Wells Fargo CEO: Fees at investment bank lower than at competitors

08:22 EDT Wells Fargo hasn't seen major changes in deposits, says CEO Scharf

08:20 EDT Faraday Future debuts all-ability aiHypercar, FF 91 2.0 Futurist Alliance - Faraday Future Intelligent Electric, a California-based global shared intelligent electric mobility ecosystem company, unveiled its "FF 91 Final Launch & Faraday Future 2.0 Event." The Company announced product upgrades since the FF 91's introduction six years ago leading into the 2.0 era of mobility and officially unveiled the release of the silicon-based new species, the FF 91 2.0 Futurist Alliance and the FF 91 2.0 Futurist. FF announced that the first phase of the Company's three phase delivery plan will commence on May 31st. A Co-creation event for the first group of industry expert users will be held on June 6. In this first phase, the Industry Expert FPO(s) will pay in full for an FF 91 vehicle in order to reserve the vehicle and be trained in the use of the vehicle. The Industry Expert FPO(s) will take possession of the reserved FF 91 vehicle at the beginning of the second phase of delivery. The FF 91 2.0 Futurist Alliance is priced at U.S MSRP of $309,000 and is currently limited to 300 units globally. Users can preorder on ff.com and FF App, where you can find the prices of the FF 91 Futurist and the FF 91. The Company also launched its mobile ecosystem product, "FF aiHypercar+," will be available for an annual subscription price of $14,900 both in the U.S. and China with the price of $100 for pre-orders.

08:17 EDT Vaxart launches new investor communication program - Vaxart announced it is launching an investor communication program that will give investors the ability to ask questions of Company management. The first event will be a fireside chat with Vaxart executives on Thursday, June 15 at 11 a.m. ET.

08:16 EDT ACI Worldwide appoints Thomas Warsop as President CEO - ACI Worldwide announced that its Board of Directors has appointed Thomas Warsop as President and Chief Executive Officer, effective June 1. Warsop, a seasoned executive and financial services technology expert, has served as Interim President and CEO since November 2022. He will also continue to serve on the ACI Board, where he has been a director since 2015. Adalio Sanchez will continue as non-executive Chair of the Board. "Since joining ACI eight years ago as a member of our Board, and as Interim President and CEO over the last six months, Tom has been instrumental in the refinement and execution of our strategic initiatives," Sanchez said. "After conducting a thorough search process, and given Tom's strong management skills, considerable expertise in financial services technology, and deep knowledge of ACI's business, strategic plan and opportunities to enhance value, the Board is confident he is the right person to continue leading our organization forward."

08:15 EDT SmileDirectClub announces U.S. launch of patented SmileMaker platform - SmileDirectClub announced the U.S. launch of its innovative SmileMaker Platform, expanding its patented technology to its largest market. "The U.S. launch of SmileMaker Platform marks a milestone in SmileDirectClub's commitment to be on the leading edge of innovation in oral care technology," said David Katzman, CEO and Chairman, SmileDirectClub. "The patented SmileMaker Platform integrates AI diagnostics and analysis into telehealth and leverages the convenience and accessibility of a mobile device, all through industry-first technology that makes it easier than ever for consumers to begin their Smile Journey and get a smile they love."

08:13 EDT Dare Bioscience publishes results of patient centered study on FSAD - Dare Bioscience announced the publication of results of the patient-centered study designed to elucidate the commonly reported symptoms, including severity of symptoms, associated with female sexual arousal disorder, FSAD. The publication, "Symptoms and associated impact in pre-and postmenopausal women with sexual arousal disorder: a concept elicitation study," appears in The Journal of Sexual Medicine. The concept elicitation study, also referred to as a content validity study, to explore the experience of condition-associated symptoms and the relative importance of FSAD symptoms, including their severity, bother, and impact, on participants' health-related quality of life in pre- and postmenopausal women with FSAD was completed prior to commencement of the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, topline data for which are anticipated during 2Q-2023. The content validity study included in-depth, qualitative, semi-structured concept elicitation interviews with premenopausal and postmenopausal women who were clinically diagnosed with FSAD by a trained sexual medicine clinician. The qualitative data from the interviews revealed a substantial physical and emotional burden of FSAD. The symptoms and impacts of this condition underscore the need for FDA-approved treatment options for pre- and postmenopausal women with FSAD. Results from this study also suggest that the manifestation and experience of FSAD are similar in pre- and postmenopausal women and that the unmet need for an FSAD treatment in the postmenopausal population is just as great as that of the premenopausal population.

08:12 EDT Reed's closes $5.6M financing transactions - Reed's announced it has closed a series of financing transactions for an aggregate of $5.6 million. Reed's closed a $4.1 million PIPE issuance led by D&D Source of Life Holding. As part of D&D's strategic investment, the Company and D&D entered into an alliance to import innovative beverage products into the US market, as well as to export Reed's robust portfolio of better-for-you products into Asia. The Company's largest shareholder, Union Square Park Capital Management, and John Bello, Chairman of the Board, also participated in the PIPE transaction. The purchase price per share was $2.585, which is based on a premium of 10% to the average of the bid and ask prices on May 19, 2023. In addition, the Company has issued warrants to purchase one share of common stock for every five shares subscribed. The warrants have an exercise price of $2.50 and a term of three years. In addition, the holders of Reed's secured convertible notes augmented their current bridge note by $1.5 million and extended the repayment date to September 29, 2023, subject to certain conditions. As part of the bridge financing, the holders also waived certain covenants. Reed's plans to use the aggregate gross proceeds of approximately $5.6 million, before deducting fees associated with the transactions payable by Reed's, for building inventory and general working capital and general corporate purposes.

08:10 EDT Bowlero to acquire all assets of Lucky Strike in $90M all-cash transaction - Bowlero announced that it has entered into a definitive agreement to acquire substantially all of the assets of Lucky Strike Entertainment, the bowling company with 14 locations across nine states. "The acquisition adds the iconic Lucky Strike brand and locations to Bowlero's expansive portfolio of bowling centers in North America, furthering its position as the leader in bowling entertainment," the company stated. Bowlero will acquire the Lucky Strike business in an all-cash transaction valued at approximately $90M. The transaction is expected to close in the first half of Bowlero's Fiscal Year 2024, and is subject to customary closing conditions...."With annual average unit volumes of over $6M, these assets offer a tremendous opportunity for the Bowlero team to apply QMS-driven optimization and grow profitability off of an already strong base. Lucky Strike posted $87M of revenue, center-level EBITDAR margin of 36%, $18M of center-level EBITDA, and $11M of consolidated EBITDA in the trailing twelve months ended March 2023," the company added.

08:10 EDT AMSC agrees to deliver nearly $20M in Wind Turbine control systems to Inox - AMSC announced it has agreed to deliver nearly $20 million of demand for its wind turbine electrical control systems, ECS, to Inox Wind Limited, including its 2-megawatt, MW, ECS and an order for its 3 MW ECS. AMSC expects to ship these systems over the course of fiscal year 2023. Daniel McGahn, Chairman, President and CEO of AMSC, stated, "We believe this 3 MW ECS order marks the beginning of our next chapter with Inox Wind as they expand their offering to include an exceptional 3 MW class wind turbine. The wind energy sector in India is finding its footing, with strong support by private and public entities. We renew our commitment to supporting Inox's growth through our proprietary technology that can enable our partners to deliver superior products to the marketplace. We are encouraged to begin scaling up production for Inox Wind and to support our partner's complete wind turbine product line with our proprietary ECS products." According to GlobalData, the Indian onshore wind market capacity is forecasted to add over 35 GW by 2030.

08:08 EDT Nokia selected by MetaLink to expand fixed wireless broadband access - Nokia (NOK) announced that it has been selected by MetaLINK (MTLK) to provide fixed wireless access coverage and boost broadband network capacity in Northwest Ohio, Northeast Indiana, and parts of Southern Michigan. Using Nokia's Citizens Broadband Radio Service, CBRS, RAN portfolio, MetaLINK will address the growing demand for broadband coverage by connecting more homes and businesses in the rural area, delivering faster speeds and increased network capacity to MetaLINK's customers. Nokia is partnering with Winncom Technologies, a global distributor of CBRS, LTE, Broadband, and FWA products, to deliver these solutions. Shaun McCarthy, President of North America Sales at Nokia, said: "We are excited to partner with MetaLINK to meet the growing fixed wireless broadband demand in Ohio. This partnership exemplifies Nokia's commitment to providing exceptional solutions that drive tangible outcomes for our customers. By leveraging our industry-leading technology, we will help narrow the digital divide and bring reliable connectivity to more communities."

08:08 EDT Bowlero to acquire all assets of Lucky Strike in $90M all-cash transaction - Bowlero announced that it has entered into a definitive agreement to acquire substantially all of the assets of Lucky Strike Entertainment, the bowling company with 14 locations across nine states. The acquisition adds the iconic Lucky Strike brand and locations to Bowlero's expansive portfolio of bowling centers in North America, furthering its position as the leader in bowling entertainment. Bowlero will acquire the Lucky Strike business in an all-cash transaction valued at approximately $90M. The transaction is expected to close in the first half of Bowlero's Fiscal Year 2024, and is subject to customary closing conditions...."With annual average unit volumes of over $6M, these assets offer a tremendous opportunity for the Bowlero team to apply QMS-driven optimization and grow profitability off of an already strong base. Lucky Strike posted $87M of revenue, center-level EBITDAR margin of 36%, $18M of center-level EBITDA, and $11M of consolidated EBITDA in the trailing twelve months ended March 2023."

08:07 EDT Aspira Women's Health announces publication of three abstracts by ASCO - Aspira Women's Health announced the online publication of three abstracts supporting the clinical utility of OvaWatch at the 2023 American Society of Clinical Oncology, ASCO, Meeting taking place in Chicago, Il on June 2-6, 2023. These abstracts were co-authored by the Aspira Women's Health Innovation Team and Dr. Gerard Reilly, Director of Clinical Research and Innovation at Axia Women's Health. The abstracts support the clinical efficacy of the newly released OvaWatch by confirming OvaWatch as an industry-leading ovarian cancer risk assessment test that can safely reduce premature surgeries in the management of adnexal masses. The abstracts can be found on the ASCO Website: Multivariate index assay to reduce preventive surgery for ovarian cancer. Serial monitoring of ovarian cancer risk in women with adnexal mass. Multivariate index assay MIA3G vs other assessment tools for the ovarian cancer risk assessment of indeterminate masses.

08:05 EDT Myriad names Brufsky as Scientific Advisor to its oncology business unit - Myriad Genetics announced it has named Adam Brufsky, MD, PhD, FACP, as Scientific Advisor to its oncology business unit. In his new role, Dr. Brufsky is responsible for guiding clinical development and medical affairs to further elevate Myriad's Precise Oncology Solutions portfolio.

08:03 EDT Aridis Pharmaceuticals receives agreement from FDA on Phase 3 study of AR-301 - Aridis Pharmaceuticals announced positive feedback from the FDA on the Company's proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus in mechanically ventilated hospitalized patients. Key agreements with FDA: FDA agreed on the design of the single confirmatory Phase 3 superiority study required to support the submission of a Biologics License Application. FDA agreed to the proposed expansion of the confirmatory Phase 3 study in S. aureus ventilator associated pneumonia patients to include ventilated hospital acquired pneumonia and ventilated community acquired pneumonia patients. The clinical efficacy endpoint will be the same endpoint of Clinical Cure of pneumonia on Day 21 used in the previous Phase 3 superiority trial AR-301-002. However, the primary efficacy endpoint will be in older adults greater than or equal to65 years of age - given that the absolute efficacy in the AR-301-002 Phase 3 study was higher in older adults than the overall population, i.e., +34% improvement on Day 21 and by +38% on Day 28 in older adults versus +11% improvement in the overall population. The confirmatory AR-301-003 Phase 3 superiority study will be powered for efficacy in both the primary efficacy endpoint in adults greater than or equal to65 years of age, and for the key secondary efficacy endpoint in all study subjects

08:03 EDT VerifyMe appoints Adam Stedham as CEO - VerifyMe announced that Adam Stedham has been appointed CEO. Stedham, who joined the Board of VerifyMe in April 2022 has been named the new CEO of VerifyMe. He will assume the position effective June 19, 2023, replacing interim CEO Scott Greenberg. Greenberg will remain in his role as Chairman of the Board but will no longer be executive chairman. "The Board of Directors is excited that Adam Stedham is becoming our CEO" stated Scott Greenberg, Chairman of the Board. "Adam's previous successful experience as CEO of GP Strategies, formally a NYSE company, eventually resulted in the sale of the Company for approximately $400M. GP Strategies' revenue grew to in excess of $450M. Adam's vision over the years enabled GP Strategies to navigate through the pandemic, integrate acquisitions, establish foreign operations, and build a strong sales team. I believe that with VerifyMe's acquisitions in the last 18 months, Adam is a great choice to take over the reins as CEO of the Company."

07:58 EDT Centerra Gold obtains EIA approval for Oksut Mine - Centerra Gold announces that the Turkish Ministry of Environment, Urbanization and Climate Change has approved the amended Environmental Impact Assessment for the Oksut mine in Turkiye. With the EIA approval in hand, along with the receipt of regulatory approvals for the mercury abatement retrofit to the adsorption, desorption and recovery plant, the Company expects to restart full operations at Oksut in the coming weeks.

07:48 EDT Brown-Forman announces $200M investment to expand Casa Herradura distillery - Brown-Forman announced plans to expand its Casa Herradura tequila distillery in Jalisco, Mexico. The approximate $200M investment will allow the company to meet the increasing global demand for its premium tequilas. Construction is expected to begin in July. The first phase will expand the water recycling and treatment plant, followed by the expansion of capacity for distilling, bottling, maturation, and processing. It builds upon Casa Herradura's commitment to environmental sustainability. Casa Herradura was a pioneer in establishing a water recycling and treatment plant that met government standards and is one of Brown-Forman's zero waste to landfill sites. Less than one percent of the solid waste generated goes to landfill, creating a more sustainable process and product. Over the past decade, Brown-Forman has made significant investments in state-of-the-art technology and implementation of processes for environmental care.

07:44 EDT Franklin Resources to acquire Putnam Investments from Lifeco for $1.7B-$1.8B - Great-West Lifeco announced that Franklin Resources operating as Franklin Templeton has agreed to acquire Putnam Investments from Lifeco. The total potential transaction consideration and retained value is estimated to be $1.7-1.8B. Franklin Templeton will pay upfront consideration of $950M-1.0B , consisting of 33.33M Franklin Templeton shares at closing and $100M in cash 6 months after closing, and up to $375M payable between 3 and 7 years after close, tied to the growth of the partnership. Lifeco will retain PanAgora, and realize the value of Putnam's seed capital, which, together with closing adjustments, are estimated to be worth $375-425 million. Lifeco will also retain certain deferred tax assets related to Putnam. Lifeco, Power Corporation of Canada and Franklin Templeton have entered a strategic partnership to distribute Franklin Templeton products for the benefit of clients, distribution partners, and shareholders. "This is a compelling transaction for Franklin Templeton, and we are excited about the numerous opportunities that will be unlocked by this long-term strategic partnership with Power and Lifeco," said Jenny Johnson, President and CEO of Franklin Templeton. "Power and Great-West Lifeco are global leaders across financial services, particularly wealth, insurance, and retirement channels. With outstanding investment performance, Putnam will add complementary capabilities to our existing specialist investment managers to meet the varied needs of our clients and will increase Franklin Templeton's defined contribution AUM. We are pleased to welcome Lifeco as a strategic investor, along with the impressive team at Putnam Investments."...The transaction is expected to close in the fourth quarter of 2023, contingent on regulatory and other customary conditions. Lifeco has agreed to retain shares representing approximately 4.9% of outstanding Franklin Templeton stock for a minimum 5-year period.

07:37 EDT Nextech3D.ai launches 'The Public Company CEO Experience Podcast' - Nextech3D.AI announced the launch of "The Public Company CEO Experience Podcast," featuring Evan Gappelberg, a three-time public company CEO and serial entrepreneur. The podcast offers listeners an exclusive behind-the-scenes look into the dynamic life of a public company CEO with valuable insights, while also discussing trending topics and providing business updates on Nexech3D.ai, Toggle3D.ai, and ARway.ai.

07:36 EDT Intellia to present updated interim data from Phase 1/2 study of NTLA-2002 - Intellia Therapeutics announced the acceptance of a late-breaking abstract from the Phase 1 portion of the ongoing NTLA-2002 Phase 1/2 study for a presentation at the European Academy of Allergy and Clinical Immunology, EAACI, Hybrid Congress 2023, taking place June 9-11 in Hamburg, Germany, and virtually. NTLA-2002 is an in vivo genome editing candidate designed to inactivate the target gene kallikrein B1, KLKB1, to permanently reduce plasma kallikrein protein levels and activity and thus prevent hereditary angioedema, HAE, attacks after a single-dose treatment. The presentation will include updated safety and efficacy results from the Phase 1 portion of the study across all three dose cohorts. Presentation Details. Title: "Updated safety and efficacy of NTLA-2002, a CRISPR/Cas9-based gene editing therapy targeting KLKB1, in a Phase 1 study of patients with hereditary angioedema."

07:35 EDT American Airlines still sees Q2 CASM-ex up 3.5%-5.5% - Sees FY23 CASM-ex up 2%-5% vs. FY22.

07:34 EDT Correction: Intellia Therapeutics did not appoint Siu as CFO

07:34 EDT Fury Gold Mines mobilizes second drill to Percival Prospect - Fury Gold Mines announces that a second drill has been mobilized to its wholly owned Eau Claire project in the Eeyou Istchee Territory in the James Bay region of Quebec. The second drill will follow up on the 2022 successes at the Percival Prospect. Drilling will consist of approximately 5,000 metres seeking to further extend the high-grade gold mineralization to the west and down dip, as well as testing some of the fourteen top priority targets along the Percival Trend/

07:33 EDT Intellia Therapeutics appoints Siu as CFO, Executive VP of Finance - Aehr Test Systems (AEHR) announced the appointment of Chris Siu as the Company's Chief Financial Officer, Executive Vice President, VP, of Finance, and Secretary effective June 1, 2023. He will succeed Ken Spink, who previously announced his planned retirement after 15 years with the Company. Spink will stay on through the completion of Aehr's fiscal 2023 year that ends May 31, 2023 and annual 10-K filing to ensure an orderly transition. Siu brings more than 27 years of finance and accounting experience in the semiconductor, medical equipment, and public accounting industries. Before joining Aehr Test Systems, he most recently served four years in senior finance executive positions at publicly traded Ultra Clean Technologies (UCTT).

07:32 EDT Lindblad Expeditions CEO Dolf Berle departs, Sven-Olof Lindblad to succeed - Lindblad Expeditions announced the departure of CEO Dolf Berle, effective June 30, who is pursuing a non-competitive opportunity in the Dallas area. Upon his departure, Lindblad Expeditions' Founder and Co-Chair of the Board of Directors Sven-Olof Lindblad will return as CEO and will work closely with Berle to ensure a smooth transition. Prior to his departure from the role, Lindblad served as CEO of Lindblad Expeditions since founding the company in 1979. In 2021, he transitioned to become Co-Chair of the Company's Board of Directors, a role which Lindblad will continue serving in. As CEO and Co-Chair, Lindblad will be instrumental in advancing the company's business strategy and growth opportunities in partnership with the Board and leadership team.

07:31 EDT Tupperware Brands: Strategic alternatives process 'underway,' 'ongoing'

07:26 EDT Algernon Pharmaceuticals receives notice of allowance for Japanese patent - Algernon Pharmaceuticals announced that it has received a Notice of Allowance from the Japanese Patent Office for patent application 2021-522114 entitled "Compositions and Methods for Treating Chronic Kidney Disease" for its lead chronic kidney disease program drug NP-251. The Company has also filed corresponding patent applications in the United States, Canada, Europe and China. The invention claims the administration of Repirinast, either alone or in combination with telmisartan, for use in the prophylaxis or treatment of renal fibrosis or kidney disease. Repirinast is the Company's lead candidate for the treatment of CKD based on data showing it reduced fibrosis by 51% with statistical significance and showed an additive benefit to telmisartan in a unilateral ureteral obstruction mouse model.

07:22 EDT Akili presents EndeavorRx data at ASCP meeting - Akili is presenting pivotal trial data on EndeavorRx in adolescents with attention-deficit/hyperactivity disorder, or ADHD, at the 2023 American Society of Clinical Psychopharmacology, or ASCP, annual meeting in Miami Beach on May 31 and at the Elevate Psych Congress in Las Vegas on June 2-3. The poster presentations highlight results of Akili's STARS-ADHD-Adolescents label expansion trial evaluating the efficacy and safety of EndeavorRx in adolescents ages 13-17 with ADHD. The multi-center open-label study enrolled 162 adolescents ages 13-17 with inattentive or combined-type ADHD. After four weeks of treatment with EndeavorRx, trial participants saw significant improvements across a wide range of clinical outcomes, including in their attention and ADHD-related symptoms. In the STARS-ADHD-Adolescents trial, EndeavorRx demonstrated a statistically significant improvement in adolescents' attention function as measured by a change in the Attention Comparison Score, or ACS, of the FDA-cleared Test of Variables of Attention, the trial's predefined primary efficacy endpoint. Nearly two-thirds of adolescents met the prespecified definition of clinical response on the TOVA-ACS. The magnitude of improvement in attention function in teenagers was nearly three times larger than what was observed in the STARS-ADHD pivotal trial in 8-12 year olds that served as the basis for EndeavorRx's FDA authorization. The mean change from baseline on the TOVA-ACS in adolescents was 2.6 as compared to 0.93 in 8-12 year olds. In exploratory responder analyses, 24.7% of participants no longer had a measurable attention deficit following treatment, achieving a TOVA-ACS of at least 0, which is in the normative range. There were also consistent clinical benefits seen across a range of secondary measures of ADHD-related symptoms and functioning. Adolescents using EndeavorRx saw significant improvement in the Attention Deficit Hyperactive Disorder Rating Scale-5 inattention subscale and total scale scores. ADHD-RS is a clinician-administered questionnaire which uses information collected from the child's caregiver. A prespecified responder analysis also showed that 27.1% of adolescents in the study demonstrated at least a 30% reduction in total scores on the ADHD-RS following EndeavorRx treatment, a finding similar to the STARS-ADHD trial in children 8-12. Statistically significant improvements were also observed for parent and child ratings of attention improvement, as well as parent ratings of function across a number of domains, including peer relationships, academic functioning, behavioral functioning, homework functioning, and self-esteem. In the study, approximately half of the teenagers used EndeavorRx by itself and the other half used it in conjunction with stimulant medication. The benefits of EndeavorRx were comparable whether it was used alone or along with stimulants. Consistent with the favorable safety profile reported in previous studies of EndeavorRx, the treatment was shown to be safe in this study, with no serious adverse events observed. A total of 4 participants experienced any adverse events, all of which were anticipated and mild or moderate, including: frustration tolerance decreased and headache. EndeavorRx is currently authorized for use in 8-12 year olds with ADHD. Based on these new data, Akili has filed with FDA to expand its current EndeavorRx label to include 13-17 year olds. In May, Akili announced topline data from a successful pivotal study of EndeavorRx in adults with ADHD 18 years of age and older, demonstrating that improvements in both objective measures of attention and clinical outcomes surpassed those seen in both pediatric and adolescent patient populations.

07:19 EDT StateHouse announces headcount reduction, explores sale of non-core assets - The company said, "While Q1 revenues declined slightly sequentially due to seasonal factors and reduced foot traffic in retail, the Company has continued to generate strong gross profit before biological asset adjustments and gross margin of $10.9 million or 44.3% of total revenue. Additionally, during Q1, the Company reduced operating expenses from the prior quarter by approximately $12.0 annualized. These reductions have been achieved through a comprehensive evaluation of Company operations, including process improvements, outsourcing of distribution, upgraded and consolidated technology, and the elimination of redundant operations and service providers. Management reduced headcount an additional 16% from January 1, 2023 to May 30, 2023. Management is also exploring the potential sale of various non-core assets, which is expected to generate approximately $1-3 million of non-dilutive capital(3) to strengthen its balance sheet and fund its growth objective"

07:11 EDT Sharecare board reauthorizes $50M share repurchase program - The company said, "Highlighting its confidence in Sharecare's long-term strategy and strong balance sheet and belief that the Company's shares represent an attractive investment opportunity, the Board has re-authorized a $50 million stock repurchase program."

07:11 EDT Sharecare concludes strategic review, continues execution of strategic plan - Sharecare announced that its Board of Directors has completed the strategic review process initiated in August 2022. After evaluating a number of alternatives with the support of advisors, the Board unanimously concluded that the best way to maximize value for shareholders at this time is to continue executing on the Company's strategic plan to drive growth and efficiencies across all three of its complementary business channels. Highlighting its confidence in Sharecare's long-term strategy and strong balance sheet and belief that the Company's shares represent an attractive investment opportunity, the Board has re-authorized a $50 million stock repurchase program. "The significant interest we received during our strategic review process not only confirmed the fundamental value of each of our business channels but, more importantly, that they are, in fact, all together better," said Jeff Arnold, chairman and CEO of Sharecare. "Our complementary capabilities, data, unified platform, and expansive customer base deliver a differentiated ecosystem for our users and clients, as well as offered the best path forward to maximize value for our shareholders." As part of the review, Sharecare's leadership also is executing an initiative to align and maximize synergies across the Company's business channels to create integrated cross-sell opportunities, foster value-added, customer-centered relationships, and accelerate long-term revenue growth. This includes: Sharecare's Enterprise platform for comprehensive care solutions - which is currently focused on the employer, health plan, and government sectors - will be actively sold to new markets including health systems, life science companies, and other healthcare stakeholders by providing the Company's connected care capabilities and extensive product portfolio via Sharecare's flexible API-as-a-Product architecture. Sharecare's Provider business channel will broaden its focus to offer Health Insight & Data Solutions, which reflect the channel's expanding customer base across a growing suite of services and extensive datasets, as it is no longer confined to traditional provider interactions given health plan contracts now constitute a large percentage of its revenue. With services that extend into population health data management, analytics, AI, and insight generation, this shift is intended to effectively represent Sharecare's ability to empower healthcare stakeholders by delivering comprehensive insight and data solutions across the spectrum. Sharecare's Life Sciences business channel will further evolve to offer broader, more robust Customer Activation & Management Solutions. Designed to acquire, engage, educate, and support people in managing their health, this channel's product suite and capabilities extend beyond pharmaceutical and biotech clients to health plans, employers, and health systems, efficiently driving targeted patient and member acquisition, increasing member enrollments into Sharecare's offerings, and furthering user engagement by leveraging extensive digital capabilities and its 100 million+ zero party database.

07:10 EDT iRhythm falls 3% to $117.51 after disclosing FDA warning letter

07:09 EDT IGM Biosciences announces FDA clearance to begin studies of imvotamab - IGM Biosciences announced that the U.S. Food and Drug Administration, FDA, has cleared two Investigational New Drug, IND, applications for imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, enabling the initiation of Phase 1b studies in both severe systemic lupus erythematosus, SLE, and severe rheumatoid arthritis, RA. The Company plans to begin patient enrollment in both multicenter clinical studies in the third quarter of 2023. "Treating autoimmune disease with T cell engagers is an exciting new field of therapeutic research, and we believe imvotamab, with its potential for deep B cell depletion, offers the opportunity to lead and transform treatment in this area," said Mary Beth Harler, M.D., President, IGM Autoimmunity and Inflammation. "Over the last two decades, CD20 has become well-established as a therapeutic target in multiple autoimmune diseases. The data from our non-Hodgkin's lymphoma clinical studies indicate that imvotamab can deplete CD20 expressing B cells, even rapidly growing lymphoma cells, with a favorable safety profile as compared with other T cell engaging CD20 x CD3 antibodies. Emerging data with cell-based therapies suggest that deep B cell depletion may have the potential to reset the immune system in patients with certain autoimmune diseases. We look forward to initiating these Phase 1b clinical trials for patients with SLE and RA in the third quarter of 2023 and fully developing the potential of imvotamab and other IgM based T cell engagers in autoimmune diseases." The primary outcome measure of the Phase 1b SLE and RA clinical trials will be the safety, tolerability, pharmacokinetics, pharmacodynamics and biologic activity of imvotamab in patients with severe SLE and severe RA who have failed multiple prior therapies.

07:08 EDT Tecnoglass to become carbon neutral effective 2023 - Tecnoglass announced it has proactively invested to offset the totality of its Scope 1 and Scope 2 carbon emissions as established by the GHG Protocol developed by the World Business Council for Sustainable Development. As part of its sustainability strategy and its goal of becoming carbon neutral, the Company has invested in carbon credits from third-party renewable energy projects equivalent to the carbon captured by over 850,000 trees. In order to assess its carbon footprint, the Company engaged a highly reputable firm to measure its emissions from 2016 through the end of 2021 and invested in carbon credits to reach neutrality through that period. Tecnoglass is currently assessing the 2022 impact and expects to invest further to achieve 2022 carbon neutrality by the third quarter of 2023. "To be a carbon neutral company has been one of our major goals for several years. We have taken several actions over the last decade to increase our energy efficiency through the use of solar panels and natural gas co-generation. Through this proactive investment we have positioned Tecnoglass to be a carbon neutral company well ahead of regional and global timetables and mandates," said Christian Daes, COO of Tecnoglass.

07:06 EDT BioRestorative receives license from NY State DoH to act as tissue bank - BioRestorative Therapies announced that it has received a license from the New York State Department of Health, DoH, to act as a tissue bank for the processing of mesenchymal stem cells from autologous donors. "This is a significant milestone for BRTX as we now can further optimize our ISO 7 certified clean room and manufacturing facility. In addition, we are exploring the ability to do contract manufacturing on behalf of other regenerative medicine companies. Our state of the art facility along with our manufacturing capabilities could provide revenues and help us offset some cash burn related to our laboratory. Finally, what is most exciting about this license is the ability to act as a tissue bank. This will enable us to bank BRTX-100 on behalf of future patients and, if FDA approved, provide those patients with an "off the shelf" autologous cell therapy product once commercially available in the United States", said CEO Lance Alstodt. There are numerous entities that are licensed to operate tissue banks and non-transplant anatomic banks in New York State. The Blood and Tissue Resources Program oversees all human tissue banking activities and services provided in New York State, from donor solicitation to clinical use. BioRestorative is the first facility in New York State to be licensed to process mesenchymal stem cells for clinical use.

07:04 EDT Selecta Biosciences presents data from Phase 3 DISSOLVE Program - Selecta Biosciences announced the presentation of data from the Phase 3 DISSOLVE I and DISSOLVE II double-blind, placebo-controlled studies of SEL-212 in patients with chronic refractory gout. SEL-212 is a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme. The data were featured during a late-breaking oral presentation at the European Alliance of Associations for Rheumatology 2023 European Congress of Rheumatology being held May 31 - June 3 in Milan, Italy. DISSOLVE I & DISSOLVE II were Phase 3, double-blind, placebo-controlled studies of SEL-212 evaluated at two doses of ImmTOR and one dose of pegadricase. In March 2023, the Company announced topline data from both studies. Data featured at EULAR 2023 Congress are summarized below. Both Phase 3 studies and both once-monthly SEL-212 doses tested met primary efficacy endpoints, achieving a statistically significant response rate, defined as the percentage of patients who achieved and maintained a serum urate less than 6 mg/dL for at least 80% of the sixth 28-day treatment period, and reductions in SU compared to placebo. The response rate in the high dose group was 56% in DISSOLVE I and 46% in DISSOLVE II. The response rate in the high dose group for patients greater than or equal to50 years old was 65% and 47% in the DISSOLVE I & II studies, respectively.For the secondary endpoint of reduction in SU from baseline, a marked reduction of approximately 60% was observed in both studies for both dose levels. SEL-212 was observed to have a favorable safety profile and well-tolerated across both doses levels.

07:03 EDT Gogo's AVANCE platform selected by flyExclusive - Gogo Business Aviation's AVANCE platform was selected by flyExclusive for upgrade on 40 private aircraft, leveraging award-winning Gogo connectivity and customer service. With flyExclusive's selection of Gogo AVANCE L3 or AVANCE L5 for installation on 40 aircraft, Gogo remains their primary provider of inflight connectivity and entertainment fleetwide. AVANCE L3 and L5 come equipped with Gogo Vision 360 which provides unlimited streaming of on-demand movies, TV programming and news, along with leading digital magazine titles and a state-of-the-art 3D moving map. Gogo Vision has a fixed monthly price which eliminates the unpredictability and often high costs associated with inflight streaming.

07:02 EDT Mastech Holdings enters into Engineering Staffing Services business - Mastech Digital announced its entry into Engineering Staffing Services business. As a provider of Data and Analytics services and IT talent to corporations globally, the company now aims to also become a trusted partner for providing engineering talent nationwide. The Engineering Staffing Services, or ESS, division of Mastech Digital will bring top engineering talent to businesses seeking highly skilled engineering professionals to drive their innovation and growth. By leveraging its extensive network built over the past three decades, Mastech Digital's newest offering will provide tailored staffing solutions to recruit reliable talent for mission-critical Engineering needs across industries like Manufacturing, Automobiles, Aerospace, Architecture, Energy, Bio-medical, Telecommunications, and Infrastructure.

06:59 EDT Visa reports May U.S. payments volume up 5% - In a regulatory filing on Tuesday, Visa announced volume and transaction data for April and from May 1-28. May U.S. payments volume on a year-over-year basis was up 5%. Credit grew 5% and Debit grew 6%. May card not present volume on a year-over-year basis was up 7%, card not present volume excluding travel was up 7% and card present volume was up 3%. May payments volume year-over-year growth for key international markets was relatively consistent with April 2023 year-over-year growth. May cross-border volume excluding intra-Europe transactions was 151% of 2019, with card not present volume excluding travel at 175% of 2019. Total card present and card not present travel cross-border volume excluding intra-Europe transactions was 139% of 2019. May travel cross-border volume into and from our Asia Pacific region and into the U.S. continued to improve relative to 2019 levels. May global processed transactions grew 9% year-over-year.

06:49 EDT Primo Water CEO Tom Harrington to retire in December - Primo Water announced that Tom Harrington, CEO and a member of the company's board of directors since January 2019, has informed the board that he intends to retire as the company's CEO, with a target effective date of December 31. To ensure a smooth transition, Harrington will continue to serve as CEO and on the board until the Board has identified and appointed a successor.

06:41 EDT Advance Auto Parts falls 22% to $87.40 after Q1 results miss, FY23 guidance cut

06:38 EDT Sanofi announces new data on frexalimab, to present at 2023 CMSC - Sanofi announces new data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers, CMSC, annual meeting, demonstrate that frexalimab, Sanofi's novel second-generation investigational anti-CD40L antibody, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis. Following 12 weeks of therapy, the number of new gadolinium-enhancing T1-lesions was reduced by 89% and 79% in the higher- and lower-dose treatment arms, respectively, compared with placebo, meeting the study's primary endpoint. Erik Wallstrom, MD, PhD, Global Head of Neurology Development, Sanofi, "Building on our 20 years of research and development in multiple sclerosis, we are committed to growing our robust pipeline of MS therapies by exploring multiple treatment approaches with unique MOAs that have the potential to slow or halt disability, which remains one of the greatest unmet medical needs in multiple sclerosis today." Pivotal trials in MS are planned to be launched in 2024.

06:35 EDT Marker Therapeutics announces pre-clinical data from product candidate MT-601 - Marker Therapeutics announced pre-clinical data from the Company's multiple tumor-associated antigens, or multiTAA,-specific T cell product candidate MT-601 in lymphoma cells, including CD19 CAR T refractory cells. Although CAR T cell therapies targeting the CD19 antigen have gained acceptance as treatment for patients with relapsed/refractory lymphoma because of their significant benefit relative to the standard of care, up to 60% of patients treated with CAR T therapies relapse within a year. MultiTAA-specific T cell therapy was investigated in the Baylor TACTAL study, which enrolled patients with both Hodgkin's and non-Hodgkin's lymphoma. The multiTAA-specific T cell product used in the TACTAL study was directed against five antigens and showed more durable clinical responses. For example, some patients who attained a complete remission with the multiTAA-specific T cell treatment were still in remission at the 72 months follow-up, suggesting a longer-lasting clinical benefit relative to published results for CD19 CAR T therapies. Given the high probability of antigen-loss associated relapse seen with CD19 CAR T therapy, Marker believes that its multiTAA-specific T cell product may result in durable responses due to its ability to overcome antigen loss by targeting more than one antigen.

06:27 EDT Parsons announces new strategic partnership with Vizsafe - Parsons announced a new strategic partnership with Vizsafe that enhances the company's capabilities to provide organizations with mission critical safety and security applications designed to keep humans healthy and safe. Parsons will utilize Vizsafe's patented Geoaware, an intelligence and safety management software platform, to optimize operational effectiveness. Vizsafe's Geoaware platform provides an intelligence dashboard that aggregates, maps, and visualizes data from a wide range of sensor networks for enhanced situational awareness, mobile communications, and analytics including incident reporting, visitor management, biosurveillance, and threat monitoring. The impact of this partnership was highlighted when the U.S. Department of Homeland Security Science and Technology Directorate Operational Experimentation Program and the National Urban Security Technology Laboratory selected Parsons and Vizsafe to participate in Urban OpEx 2022 to evaluate the Geoaware platform in the hands of first responders from agencies around the country.

06:06 EDT Donaldson sees FY23 CapEx $115M-$130M - Free cash flow conversion is forecast between 105% and 115%. For the full year, Donaldson expects to repurchase approximately 2% of its shares outstanding.

05:56 EDT Unilever announces CFO, chief digital and commercial officer to leave - Unilever announced that Graeme Pitkethly, CFO, has informed the Board of his intention to retire from the company by the end of May 2024. The Board will now proceed with a formal internal and external search for his successor. Unilever CEO Alan Jope said: "I would like to thank Graeme for his tremendous contribution to Unilever over the last 21 years." In addition, Conny Braams, Chief Digital and Commercial Officer and member of the Unilever Leadership Executive, has decided to leave Unilever in August 2023. Conny's successor will be announced in due course, Unilever said. Reference Link

05:25 EDT Stellantis, Vulcan Energy Resources sign term sheet for new geothermal projects - Stellantis and Vulcan Energy Resources have signed a binding term sheet for the first phase of a multiphase project to develop new geothermal projects aimed at decarbonizing the energy mix of Stellantis' Mulhouse industrial site in France, which is home to the DS 7, Peugeot 308 and e-308, 508, and the new 408. Based upon current assumptions, the project could provide a significant portion of the industrial site's annual energy needs starting in 2026. The first phase of the project, located at the southernmost extent of Vulcan's focus area in the Upper Rhine Valley, will include a pre-feasibility study for the construction of geothermal renewable energy assets for Stellantis' facility, carried out by Vulcan which will also assess potential for lithium production. If successful, the next phase will focus on 3D seismic exploration and more advanced studies and development. Subject to a successful PFS, Stellantis and Vulcan aim to develop the project jointly on a 50:50 basis. In November 2022, Vulcan announced that it had started a number of initiatives to expand its geothermal renewable energy and Zero Carbon Lithium business into France and specifically Alsace, which accounts for roughly one third of the Upper Rhine Graben. Vulcan has applied over the Mulhouse area for an exclusive lithium and geothermal license to secure another 480 km of development area within the Upper Rhine Graben Valley Brine Field. According to the term sheet, Vulcan's team will perform a lithium mineral resource assessment according to the JORC Code. Vulcan Zero Carbon Lithium project is aligned with the creation of the "French Mineral Resources Observatory" that aims to analyze the French critical raw materials resources and provide recommendations for public investment that will be supported by the recently announced new 2 billion euro "French Critical Raw Materials Fund".

05:19 EDT AbbVie announces SLEek study meets primary, key secondary endpoints - AbbVie announced the results of the Phase 2 SLEek study evaluating upadacitinibalone and in combination in adults with moderately to severely active systemic lupus erythematosus, ot SLE, who continued to receive standard lupus therapies. The study results are being presented as an oral presentation during the European Congress of Rheumatology. In the Phase 2 SLEek study, a greater proportion of patients receiving upadacitinib 30 mg or ABBV-599 high dose achieved the primary endpoint, SLE Responder Index and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24, compared to placebo. SRI-4 and steroid dose less than or equal to 10 mg prednisone equivalent per day assess reductions in disease activity and glucocorticoid use, respectively. Key secondary endpoints were also achieved at week 48 in both active treatment groups, including lupus flares measured by the Safety of Estrogens in Lupus Erythematosus National Assessment, or SELENA, Systemic Lupus Erythematosus Disease Activity Index, or SLEDAI, Flare Index, or SFI, and time to first flare, which showed greater treatment effect in the upadacitinib 30 mg and ABBV-599 high dose groups compared to placebo.2 Other measures of disease activity and treatment response were also met, including achievement of BICLA response, SRI-4, and Lupus Low Disease Activity State, or LLDAS, in the upadacitinib 30 mg and ABBV-599 high dose groups compared to placebo. No new safety signals were observed beyond the known safety profile for upadacitinib.2 Types of adverse events reported with ABBV-599 high dose were similar to those reported for patients treated with upadacitinib alone. The rate of treatment emergent adverse events, or TEAEs, in this study were similar across groups. Serious AEs were reported in 10.3% of patients in the ABBV-599 high dose, 21% in upadacitinib 30 mg, and 17.3% in placebo groups. Adjudicated cardiovascular events were reported in one patient in each of the three treatment groups. There were no reports of malignancies or venous thromboembolic events. The use of upadacitinib and elsubrutinib in SLE are not approved and their safety and efficacy have not been evaluated by regulatory authorities.

05:09 EDT Qualtrics opens new EMEA headquarters in Dublin City Centre - Qualtrics announced it has opened its new Europe, Middle East and Africa, or EMEA, headquarters in Dublin City Centre, which will feature an XM Innovation Centre focused on AI. The opening of the building marks 10 years of investment and expansion in Ireland by Qualtrics, since the U.S.-headquartered company set up a Dublin base as its first office outside of the United States in 2013. Costello House is Qualtrics largest office in EMEA and the base for the company to target further international expansion. The Dublin office will also house a planned R&D XM Innovation Centre. Costello House has capacity for over 500 employees and an Executive Briefing Centre for customers from across EMEA.